SLC2A5 Antibody

What is SLC2A5 and why is it a significant research target?

SLC2A5 (Solute Carrier Family 2 Member 5), also known as GLUT5, is the primary fructose transporter in mammalian cells. It belongs to the solute carrier 2 family and the major facilitator superfamily of membrane transporters. The protein contains 12 membrane-spanning domains, an N-linked glycosylation site, and intracellular NH2 and COOH termini .

SLC2A5 is particularly significant for research into:

• Fructose metabolism disorders

• Cancer metabolism (notably in AML, pancreatic, and hepatocellular carcinomas)

• Metabolic syndrome and obesity

• Intestinal transport physiology

Research has demonstrated that SLC2A5 upregulation is associated with poor clinical outcomes in certain cancers, and pharmacological inhibition of SLC2A5 can ameliorate leukemic phenotypes and potentiate chemotherapy efficacy .

How do I select the appropriate SLC2A5 antibody for my research application?

Selection criteria should be based on:

Key factors to consider:

• Species reactivity: Ensure reactivity with your experimental species (human, mouse, rat)

• Epitope location: N-terminal, C-terminal, or middle region antibodies may perform differently depending on protein conformation in your application

• Validation data: Review literature and product documentation showing successful use in your specific application

• Clone specificity: For monoclonals, check if specific clones (e.g., OTI14C8, OTI9F3) have been validated for your application

What are the optimal conditions for Western blotting with SLC2A5 antibodies?

Western blotting for SLC2A5 requires specific optimization:

Protocol recommendations based on published research:

• Sample preparation:

  • Use membrane fractions or total cell lysates (30-50 μg protein/lane)

  • Include protease inhibitors to prevent degradation

• Gel separation:

  • 5-20% gradient SDS-PAGE gel at 70V (stacking)/90V (resolving)

  • Run for 2-3 hours for optimal separation

• Transfer conditions:

  • Transfer to nitrocellulose membrane at 150mA for 50-90 minutes

  • Wet transfer systems generally yield better results for this membrane protein

• Blocking:

  • 5% non-fat milk in TBS for 1.5 hours at room temperature

• Primary antibody incubation:

  • Dilution range: 1:200-1:400 (0.5-2.5 μg/ml) depending on antibody

  • Overnight incubation at 4°C for optimal binding

• Detection:

  • HRP-conjugated secondary antibodies at 1:5000-1:10000 dilution

  • Enhanced chemiluminescence detection systems

Expected result: SLC2A5 typically appears as a band at approximately 55 kDa, though glycosylation can cause slight variations in molecular weight .

How should I optimize immunohistochemistry protocols for SLC2A5 detection in tissue samples?

Based on validated protocols from multiple sources:

• Sample preparation:

  • For paraffin sections: 4-5 μm sections on positively charged slides

  • For frozen sections: 8-10 μm cryosections fixed with paraformaldehyde

• Antigen retrieval (critical step):

  • Heat-mediated retrieval in citrate buffer (pH 6.0) for 20 minutes

  • This step is essential for breaking protein crosslinks formed during fixation

• Blocking:

  • 10% serum (matched to secondary antibody species) for 1 hour

  • Include 0.3% Triton X-100 if detecting intracellular domains

• Primary antibody:

  • 1:200 dilution (approximately 1-2 μg/ml) is optimal for most validated antibodies

  • Incubate overnight at 4°C in a humidified chamber

• Detection systems:

  • For chromogenic detection: Streptavidin-biotin complex with DAB chromogen

  • For fluorescence: Secondary antibodies conjugated to fluorophores (AlexaFluor-488 works well)

Expected staining patterns:

• Small intestine: Strong apical membrane staining of enterocytes

• Brain: Staining in pyramidal layer of hippocampal CA3 region and Purkinje cell layer in cerebellum

• Cancer tissues: Variable expression depending on tumor type, with membranous and sometimes cytoplasmic staining

How can SLC2A5 antibodies be used to investigate cancer metabolism and potential therapeutic targets?

SLC2A5 antibodies are valuable tools for studying cancer metabolism, particularly in investigating fructose utilization as an alternative energy source:

Research applications with methodological approaches:

• Expression profiling across cancer types:

  • Use IHC with tissue microarrays to screen SLC2A5 expression across tumor types and correlate with clinical outcomes

  • Multiple studies show increased SLC2A5 expression correlates with poor prognosis in hepatocellular carcinoma, pancreatic cancer, and acute myeloid leukemia

• Mechanistic studies of fructose metabolism:

  • Western blotting to quantify SLC2A5 expression following genetic or pharmacological interventions

  • Combine with metabolic assays (fructose uptake, ATP production) to correlate transporter expression with functional outcomes

• Therapeutic target validation:

  • CRISPR/Cas9-mediated inactivation of SLC2A5 significantly inhibits cancer cell proliferation and migration in vitro and reduces metastasis

  • Antibodies can confirm knockout/knockdown efficiency and monitor for compensatory upregulation of other glucose transporters (SLC2A1, SLC2A2, SLC2A4)

• Monitoring treatment response:

  • Flow cytometry with SLC2A5 antibodies can track changes in transporter expression in response to metabolic inhibitors

  • Particularly relevant for development of fructose metabolism-targeting therapeutics

Research findings demonstrate that the fructose-binding/transport activity of SLC2A5 is essential for enhanced motility of cancer cells, as evidenced by rescue experiments where wild-type SLC2A5 restored cellular proliferation and motility in gene-edited cancer cells, while the E401A mutant (with 90% reduced fructose binding capacity) did not .

How should I interpret contradictory results when comparing SLC2A5 protein expression by Western blot versus immunohistochemistry?

Discrepancies between Western blot and IHC results for SLC2A5 are not uncommon and require careful interpretation:

Methodological considerations for resolving contradictions:

• Sample preparation differences:

  • Western blot involves denatured protein, exposing epitopes that may be masked in native conformation

  • IHC preserves tissue architecture but may mask epitopes through fixation or processing

• Antibody epitope location:

  • N-terminal antibodies may yield different results than C-terminal antibodies due to potential proteolytic processing or membrane topology

  • Middle region antibodies (AA 232-251) may detect different conformational states

• Technical validation approaches:

  • Perform blocking peptide controls to confirm antibody specificity

  • Use multiple antibodies targeting different epitopes to validate findings

  • Include known positive and negative control tissues/cell lines

• Biological interpretation of discrepancies:

  • Higher IHC signal with lower Western blot band intensity may indicate post-translational modifications affecting epitope recognition

  • Different subcellular localization patterns may reflect trafficking rather than expression changes

Research example: In studies of SLC2A5 in brain tissue, Western blot detected expression in mouse and rat brain membranes, while IHC revealed specific localization to pyramidal and Purkinje cells , demonstrating how these techniques provide complementary rather than contradictory information.

What strategies can resolve weak or absent signal when using SLC2A5 antibodies in Western blotting?

When facing weak or absent signals in Western blotting for SLC2A5, consider these methodological approaches:

• Protein extraction optimization:

  • SLC2A5 is a membrane protein requiring specialized extraction methods

  • Use membrane fractionation protocols with non-ionic detergents (0.5-1% Triton X-100 or NP-40)

  • Avoid excessive heat during sample preparation (keep below 70°C)

• Sample preparation considerations:

  • Ensure samples contain adequate protein concentration (50-100 μg total protein per lane)

  • Include protease inhibitors to prevent degradation

  • For tissues with known low expression, consider enrichment through immunoprecipitation before Western blotting

• Antibody selection and optimization:

  • Try antibodies targeting different epitopes (N-terminus vs. C-terminus vs. middle region)

  • Adjust antibody concentration (try a range from 0.5-5 μg/ml or 1:100-1:1000 dilution)

  • Extend primary antibody incubation to overnight at 4°C

• Detection system enhancement:

  • Use high-sensitivity ECL substrates for HRP-conjugated secondaries

  • Consider signal amplification systems like biotin-streptavidin detection

  • Ensure secondary antibody compatibility with primary antibody host species

• Validation approaches:

  • Include positive control samples (small intestine for SLC2A5)

  • Test alternative antibody clones if available

  • Consider membrane protein enrichment protocols specific for transporters

Published data shows that rat small intestine lysate is an excellent positive control, with clear bands at ~55 kDa, while mouse kidney samples may show weaker expression requiring optimization .

How can background staining be minimized when using SLC2A5 antibodies for immunohistochemistry?

High background is a common challenge in SLC2A5 immunohistochemistry that can be addressed through systematic optimization:

• Blocking optimization:

  • Increase blocking serum concentration to 10-15%

  • Add 0.1-0.3% Triton X-100 to reduce non-specific hydrophobic interactions

  • Consider dual blocking with both serum and 3-5% BSA

• Antibody dilution and incubation conditions:

  • Titrate antibody concentration (typical range 1:100-1:500)

  • Extend primary antibody incubation to overnight at 4°C

  • Increase wash duration and volume after antibody incubations

• Tissue-specific considerations:

  • For tissues with high endogenous peroxidase (liver, kidney), use additional H₂O₂ quenching steps

  • For tissues with high biotin content, use avidin-biotin blocking kits

  • For autoimmune or mast cell-rich tissues, consider blocking endogenous IgG

• Detection system optimization:

  • Use polymer-based detection systems that can reduce background compared to biotin-based methods

  • For fluorescent detection, include an additional blocking step with 10% normal serum from the host species of your secondary antibody

• Validated controls:

  • Always include a secondary-only control to assess non-specific binding

  • Use tissues known to be negative for SLC2A5 as negative controls

  • Consider preincubation with blocking peptide as specificity control

How can SLC2A5 antibodies be applied in flow cytometry to study fructose transporter expression in heterogeneous cell populations?

Flow cytometry with SLC2A5 antibodies enables quantitative analysis of transporter expression at the single-cell level:

Optimized methodology based on published protocols:

• Cell preparation considerations:

  • For surface epitopes: Gentle enzymatic dissociation preserves epitope integrity

  • For intracellular epitopes: Fixation with 4% paraformaldehyde followed by permeabilization with 0.1% saponin or 0.3% Triton X-100

• Antibody selection and staining protocol:

  • Use flow cytometry-validated antibodies (e.g., clones OTI14C8, OTI9F3)

  • Optimal concentration: 1-3 μg per 10⁶ cells

  • Incubation: 30 minutes at room temperature or 4°C (temperature depends on epitope accessibility)

• Controls and validation:

  • Isotype control at matching concentration to assess non-specific binding

  • Unstained cells to establish autofluorescence baseline

  • Cells with known high SLC2A5 expression (e.g., intestinal epithelial cells, certain cancer cell lines) as positive controls

  • Consider using SLC2A5 knockout or siRNA-treated cells as negative controls

• Multiparameter analysis strategies:

  • Combine with cell type-specific markers to identify SLC2A5 expression in specific subpopulations

  • Include viability dye to exclude dead cells that may bind antibodies non-specifically

  • For cancer studies, combine with stemness markers to assess SLC2A5 expression in cancer stem cells

Published research demonstrates successful application of this approach in THP-1 cells, where clear population shifts were observed following staining with anti-SLC2A5 antibody compared to isotype control .

What methodological considerations are important when using SLC2A5 antibodies to investigate the role of fructose metabolism in disease models?

Investigating fructose metabolism in disease models using SLC2A5 antibodies requires careful experimental design:

• Model system selection and validation:

  • Verify SLC2A5 expression in your model system by Western blot before detailed studies

  • Consider species differences in SLC2A5 expression patterns when selecting animal models

  • For cell culture models, validate fructose transport functionality (not just transporter expression)

• Experimental design for mechanistic studies:

  • Combine antibody-based protein detection with functional assays (fructose uptake, metabolomics)

  • Design time-course experiments to capture dynamic changes in SLC2A5 expression

  • Consider compensatory upregulation of other transporters when manipulating SLC2A5 expression

• Genetic manipulation approaches:

  • When using CRISPR/Cas9 for SLC2A5 knockout, target conserved exons (e.g., Exon 3)

  • Validate knockout efficiency by both genomic sequencing and protein expression analysis

  • For rescue experiments, use both wild-type SLC2A5 and function-deficient mutants (e.g., E401A) to demonstrate specificity

• Translational considerations:

  • Correlate SLC2A5 expression with clinical outcomes in patient samples

  • Meta-analysis of multiple datasets has demonstrated hazard ratios of 1.87 (95% CI, 1.24-2.50) for high SLC2A5 expression in AML

  • Combine tissue microarray analysis with patient survival data to establish clinical significance

Research example: Studies have demonstrated that CRISPR/Cas9-mediated inactivation of SLC2A5 inhibits cancer cell proliferation and migration in vitro and reduces metastasis, with functional rescue only achieved by wild-type but not E401A mutant SLC2A5, confirming the specific role of fructose transport activity in cancer cell behavior .